8-KLeadership Changes

Philip Morris International Inc. 8-K Report, Executive Changes (Dec 14, 2022)

Filed December 14, 2022For Securities:PM

Summary

Philip Morris International Inc. (PM) filed an 8-K on December 13, 2022, detailing key executive appointments and compensation adjustments. The most significant change is the appointment of Jorge Insuasty as the full-time President of Vectura Fertin Pharma, effective January 1, 2023. This move signifies a dedicated leadership focus for this important segment of the business, with Mr. Insuasty continuing to report directly to CEO Jacek Olczak and no change to his compensation. Additionally, the filing outlines compensation adjustments for Frederic de Wilde, who is transitioning to a broader regional leadership role covering South and Southeast Asia, CIS, the Middle East, and Africa. These adjustments include a promotion in salary grade, an increased base salary to CHF 1,000,008, and revised annual incentive and equity award targets. These organizational realignments underscore PM's ongoing strategic adjustments and focus on key growth areas.

Key Highlights

  • 1Jorge Insuasty appointed full-time President, Vectura Fertin Pharma, effective January 1, 2023.
  • 2Mr. Insuasty will no longer serve as Chief Life Sciences Officer; Badrul Chowdhury (Chief Life Sciences Officer, Smoke-Free Products) will report directly to the CEO.
  • 3No changes to Mr. Insuasty's compensation arrangements associated with his new role.
  • 4Frederic de Wilde appointed President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region.
  • 5Mr. de Wilde's base salary increased to CHF 1,000,008 (approx. $1,080,009).
  • 6Mr. de Wilde's annual incentive compensation target set at 125% of new base salary.
  • 7Mr. de Wilde's equity award target set at 275% of new base salary.

Frequently Asked Questions

The appointment of Jorge Insuasty to a full-time role as President of Vectura Fertin Pharma indicates a strategic prioritization and dedicated leadership focus on this specific business segment, suggesting its importance to Philip Morris International's future growth strategy.

Badrul Chowdhury, the Chief Life Sciences Officer for Smoke-Free Products, will now report directly to CEO Jacek Olczak. This change occurs as Jorge Insuasty steps down from his dual role as Chief Life Sciences Officer to fully focus on his presidency at Vectura Fertin Pharma.

Frederic de Wilde will receive a base salary increase to CHF 1,000,008 (approximately $1,080,009). His annual incentive compensation target has been set at 125% of his new base salary, and his equity award target is now 275% of his new base salary, reflecting his expanded regional responsibilities.

This 8-K filing primarily concerns executive appointments and compensation adjustments, not a change in financial performance or outlook. While these leadership moves are strategic, their direct financial impact is not detailed in this filing. Investors should refer to other SEC filings, such as quarterly earnings reports, for financial performance updates.